title: Capecitabine-related neurotoxicity presenting as trismus.
abstract: Capecitabine is an oral fluoropyrimidine used for cancer treatment. It is generally well tolerated. A patient who had previously received adjuvant 5-fluorouracil without neurotoxicity had a severe adverse reaction when later given capecitabine in the metastatic setting. She presented with the acute onset of neuromuscular symptoms, the most prominent being trismus but also including slurred speech, confusion, gait abnormalities, and ocular changes. Her symptoms completely resolved with discontinuation of capecitabine.
authors.affiliation: Department of Medicine, University of Wisconsin, Madison, USA.
authors.forename: Linda S B
authors.initials: LS
authors.lastname: Couch
authors.forename: David L
authors.initials: DL
authors.lastname: Groteluschen
authors.forename: James A
authors.initials: JA
authors.lastname: Stewart
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Mulkerin
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000069287:Capecitabine; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology*; D003221:Confusion / Q000209:etiology; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004569:Electroencephalography; D005133:Eye Movements; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D020234:Gait Ataxia / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013064:Speech Disorders / Q000209:etiology; D014313:Trismus / Q000139:chemically induced*
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil